Recently published data on the combined activity of pioglitazone and COX-2 inhibitors in metastatic cancer approved that cancer encompasses other diseases, such as inflammation: Similarly to non-malignant typically inflammation-linked diseases, pioglitazone (peroxisome proliferator-activated receptor-gamma, PPAR-γ agonist) may induce response in malignant diseases such as e.g., vascular sarcomas while attenuating the host’s inflammatory reaction to metastatic disease [Vogt et al. 2003; Reichle et al. 2004]. The gene discussed is PPARG; the disease is vascular sarcoma.